Vaccine Organization Vaccine Type Reason Final Results Herpevac, Simplirix GlaxoSmithKline Prophylactic, Sub Unit gD2t with alum/MPL adjuvant AS04[65][2] Failed in Phase III clinical trial[66] No statistically significant results found[67] No effect regarding HSV-2 was achieved, partial protection against HSV-1 confirmed[68] Unnamed[69] PaxVax Recombinant Vector Vaccine[70] Discontinued in pre-clinical stage, no longer appears in company's pipeline[71] N/A ImmunoVEX HSV2 vaccine Amgen, BioVex Live, Attenuated, defective in immune evasion[72] Discontinued in Phase I stage, no longer appears in company's pipeline[73] N/A Gen-003 Genocea Sub Unit gD2/ICP4 with Matrix M2 adjuvant Discontinued after Phase II stage 58% Reduction in Viral Shedding, 69% Reduction in Outbreaks. Spending on vaccine has ceased.[74] AuRx Herpes Vaccine AuRx[75] Recombinant Vector Vaccine[76] Inactive N/A DISC vaccine[77] Cantab Pharmaceuticals Live, Attenuated HSV vaccine with gH deleted Discontinued in Phase I stage No clinical or virological benefit was shown Unnamed[78] Mymetics ? Discontinued in pre-clinical stage, no longer appears in company's pipeline N/A HerpV Agenus Peptide vaccine/QS-21 adjuvant Discontinued after Phase II stage[79] N/A VCL-HB01[80] Vical DNA vaccine: gD2+UL46/Vaxfectin adjuvant Discontinued after Phase II stage Trial did not show positive outcome.[81]